Researchers at the Institute of Genetics and Cancer are launching a £1.5 million Cancer Research UK-funded study to find a way to ‘trick’ bowel cancer cells. Magenta shows aspect in cancer cells that the immune system can now see to attack Cancer cells can often disguise themselves, preventing the immune system from recognising them as a threat and destroying them. The team aims to disrupt cancer’s DNA messaging system, causing errors that make the cells visible to immune defences.Exploring how to trigger this vulnerability, the study’s long-term goal is to identify new treatments to tackle bowel cancer more effectively. Around 85 per cent of patients with bowel cancer find immunotherapy isn’t effective for them. Our new project aims to explore why and find new ways to make bowel cancer more responsive to this type of treatment.Immunotherapy is exciting as it has the potential be curative, not just manage the disease, and has the benefit of reducing side effects to patients.We hope this project will find a way to shine a light on bowel cancer cells so they are no longer invisible to our immune system, by disrupting the messages telling cancer cells to grow. Dr Kevin Myant Cancer Research UK Career Development Fellow Often, in cancer, the immune system doesn’t see cancer cells as a threat as they are generated from inside the body.This research will focus on the body’s messaging system, RNA, which takes information from DNA and tells cells when to grow and where.The team aims to sabotage this system, through a process called RNA splicing, to disrupt these messages and introduce errors which will effectively 'light up' bowel cancer cells to the immune system so it can destroy them. Immunotherapies, where a patient’s own immune system is harnessed to tackle cancer, are a key area of cancer research and for some patients, they are providing transformational improvements but not all patients respond to them.Being able to use the power of our own immune system to tackle cancer could offer more effective treatments and lead to the kind of breakthroughs which can revolutionise cancer treatment and care.We need more research to understand the differences in patient responses to therapies and how to improve these and Cancer Research UK is delighted to fund this innovative and potentially transformative research. Dr Catherine Elliott Cancer Research UK Director of Research Related Links Kevin Myant Research Group Image credit: Aslihan Bastem Tags 2026 Publication date 07 Apr, 2026